Phase 2 march study: Atg-010 plus low dose dexamethasone in chinese relapsed/refractory multiple myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMID) and a proteasome inhibitor (PI)

Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: 84cce761dfac59689f09068745fc64f4c4d81d1b
First added on: Feb 13, 2025